Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. reported a net income of $4.232 million for the third quarter of 2026, a substantial turnaround from a net loss of $29.781 million in the same period of 2025. However, total revenues decreased to $1.434 million from $3.681 million year-over-year, while operating expenses rose to $8.748 million. The company's cash position decreased, and total liabilities saw a significant reduction, primarily due to a decrease in warrant liabilities.

Lineage Cell Therapeutics announced the acquisition of NeuroAirmid Therapeutics, adding the clinical-stage HUNT1 program for Huntington's Disease to its pipeline. The acquisition includes rights to the ongoing REGEN4HD Phase 1b/2a clinical study. Lineage also reported its third quarter 2026 financial results, showing a net income of $4.2 million, largely due to a non-cash fair value remeasurement of warrant liabilities. Additionally, the company secured a U.S. patent for its AlloSCOPE "5D" cell manufacturing technology.

Lineage Cell Therapeutics reported a net income of $1.48 million for the second quarter of 2026, a significant improvement from a net loss of $30.46 million in the same period last year. This turnaround was primarily driven by a gain from the change in fair value of warrant liability and the absence of a prior year intangible asset impairment loss, despite a decrease in total revenues. The company's cash, cash equivalents, and marketable securities stood at $50.8 million, supporting operations for at least the next twelve months.

Lineage Cell Therapeutics reported a net income of $1.5 million for Q2 2026, a significant improvement from a $30.5 million net loss in Q2 2025, with basic EPS of $0.01. The company's cash, cash equivalents, and marketable securities of $50.8 million are expected to fund operations into Q3 2028. Key business updates include positive 3-year clinical data for OpRegen, progress with the COR1 corneal endothelial disease program, and advancements in other pipeline assets like OPC1, ILT1, and ReSonance.

Lineage Cell Therapeutics withdrew its application for a Clinical Trial (CLIN2) award from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of OPC1 for spinal cord injuries. The company stated this withdrawal does not impact its current and planned development of OPC1. Additionally, at its annual meeting, shareholders elected seven directors, ratified Baker Tilly US, LLP as the independent registered public accounting firm for 2026, and approved executive officer compensation on an advisory basis.

Lineage Cell Therapeutics reported a net loss attributable to Lineage of $(4.81) million for the first quarter of 2026, an increase from $(4.14) million in the prior year. Total revenues increased to $1.73 million from $1.50 million, driven by higher collaboration revenues. The company ended the quarter with $53.4 million in cash, cash equivalents, and marketable securities, and believes this is sufficient to fund operations for at least the next twelve months.

Lineage Cell Therapeutics reported a net loss of $(4.8) million for Q1 2026, an increase from $(4.1) million in Q1 2025, with total revenues rising to $1.7 million. The company also announced significant business advancements, including positive 3-year Phase 1/2a clinical data for OpRegen, the launch of its new COR1 corneal endothelial disease cell therapy program, and the treatment of a second patient in the OPC1 DOSED study. Additionally, Lineage established a Scientific Advisory Board and appointed a new SVP & Head of Clinical. The company expects its cash to support operations into Q2 2028.

Lineage Cell Therapeutics, Inc. announced its 2026 Annual Meeting of Shareholders to be held on June 10, 2026. Shareholders will vote on the election of seven directors, the ratification of Baker Tilly US, LLP as the independent registered public accounting firm for fiscal year 2026, and an advisory approval of named executive officer compensation. The record date for voting was April 20, 2026, with 249,298,295 common shares outstanding. The filing also detailed non-employee director compensation for 2025, including cash fees and annual stock option grants of 75,000 shares.

Lineage Cell Therapeutics, Inc. filed its definitive proxy statement for the 2026 Annual Meeting of Shareholders, scheduled for June 10, 2026. Shareholders will vote on the election of seven directors, the ratification of Baker Tilly US, LLP as the independent registered public accounting firm for fiscal year 2026, and an advisory vote on named executive officer compensation. The filing also details non-employee director compensation, including annual cash fees and stock option grants, and outlines the company's corporate governance practices.